CD99 inhibitors and their uses
US11202792B2 · kind B2 · utility
0Cited by
5References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 12, 2017 |
| Grant date | Dec 21, 2021 |
| Priority date | — |
| Expiry date | Oct 12, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods of treating a bone or connective tissue cancer in a subject. The methods comprise administering to the subject an effective amount of a CD99 inhibitor, wherein the CD99 inhibitor is a compound having the formulawherein R, each of which may be the same or different, is hydrogen, or a protecting group; wherein Z is selected from the group consisting of F, Cl and Br; wherein X is H or F; and pharmaceutically acceptable salts thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.